Indoco Remedies Limited Stock Price Today (NSE: INDOCO)

Indoco Remedies Limited

254.00+12.61 (+5.22%)
Market Closed

Fundamental Score

...

Indoco Remedies Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Indoco Remedies Limited share price today is 254.00, up +5.22% on NSE/BSE as of 16 September 2026. Indoco Remedies Limited (INDOCO) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of 2.34K (Cr). The 52-week high for INDOCO share price is 325.00 and the 52-week low is 162.19. At a P/E ratio of 793.75x, INDOCO is currently trading above its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of -9.70% and a debt-to-equity ratio of 1.10.

Indoco Remedies Limited Share Price Chart — NSE/BSE Historical Performance

No data
High
287.80
Low
214.06
Volume
12.5L
Change
+14.83%

Indoco Remedies Limited share price chart: 14.83% return over the past month. 52-week high ₹325.00, 52-week low ₹162.19.

Indoco Remedies Limited — Last 10 Trading Days

DateOpenHighLowCloseVolume
241.39258.00235.00254.006.44L (Cr)
263.02265.92238.50241.393.55L (Cr)
260.00276.98251.50263.0250.02L (Cr)
234.94269.90229.00254.2560.15L (Cr)
242.00246.29229.50231.185.70L (Cr)
250.73256.88243.00244.251.76L (Cr)
249.30257.24248.06250.703.15L (Cr)
272.95274.70260.59262.513.69L (Cr)
273.36283.50266.38272.5614.90L (Cr)
242.00287.80241.34273.77192.25L (Cr)

Indoco Remedies Limited — Last 12 Months Price History

MonthOpenHighLowCloseChange
243.34287.80229.00254.00+4.38%
222.78253.70214.06243.34+9.23%
237.00268.00216.03219.49-7.39%
210.00261.71198.00239.22+13.91%
211.10270.00191.00209.66-0.68%
169.90227.85167.61209.49+23.30%
195.00206.09162.19164.00-15.90%
210.00246.70195.00202.28-3.68%
235.60235.60202.96217.51-7.68%
257.70262.50222.00234.60-8.96%
282.00288.00250.10256.15-9.17%
287.55317.35270.70279.15-2.92%

Returns & Performance

Poor

Return on Equity (ROE)

-9.70%

Profit generated per ₹1 of shareholder equity

Poor

Return on Capital (ROCE)

1.00%

Returns generated on total capital deployed

Excellent

Oper. Profit Margin (5Y Avg)

13.59%

Average operating profit margin over 5 years

Dividend Yield

0.08%

Annual dividend as % of current share price

Indoco Remedies Limited Valuation Check

Poor

Price to Earnings (P/E)

793.75x

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

34.89x

Average P/E of all peers in this sector

Market-cap Classification
Small-cap
Higher growth potential with higher volatility.

Shareholding Pattern

Excellent

Promoter Holding

58.90%

% shares held by company founders/management

Poor

FII Holding

0.94%

% shares held by foreign institutional investors

Good

DII Holding

18.15%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Poor

Profit Growth (Quarterly YoY)

-281.59%

Net profit growth vs same quarter last year

Poor

Revenue Growth (Quarterly YoY)

6.76%

Revenue growth vs same quarter last year

Poor

Revenue Growth (5-Year CAGR)

8.25%

Compounded annual revenue growth over 5 years

EPS Growth (5-Year CAGR)

N/A

Earnings per share growth over 5 years

Net Profit Growth (5-Year CAGR)

N/A

Compounded annual net profit growth over 5 years

Balance Sheet Health

Poor

Debt to Equity Ratio

1.10x

Total debt ÷ equity. Below 0.5 = financially healthy

Poor

Interest Coverage Ratio

0.13x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

-105.13 (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Indoco Remedies Limited Fundamental Analysis & Valuation Benchmarking

Educational evaluation of INDOCO across key market metrics for learning purposes.

Positive Indicators

2 factors identified

Balanced Promoter Holding (58.90%)

Observation: Optimal balance between promoter control and public float.

Analysis: Promoter holding in 50-75% range provides management alignment.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

7 factors identified

Below-Average Return on Equity (-9.70%)

Observation: Returns on equity are below industry benchmarks.

Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.

Suboptimal ROCE (1.00%)

Observation: Returns on capital employed are below expectations.

Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.

Premium Valuation Risk (P/E: 793.75x)

Observation: High valuation multiples may limit upside potential.

Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.

Profit Decline Concern (-281.59%)

Observation: Significant year-over-year profit contraction observed.

Analysis: Declining profitability requires investigation into underlying causes.

Elevated Debt Levels (D/E: 1.10)

Observation: High leverage increases financial risk and interest burden.

Analysis: High debt-to-equity ratios require monitoring of debt servicing capability.

Weak Interest Coverage (0.13x)

Observation: Limited ability to service debt obligations from earnings.

Analysis: Low interest coverage raises concerns about financial stability.

Negative Free Cash Flow (₹-105.13 Cr over 5Y)

Observation: Cash outflows exceed inflows.

Analysis: Negative FCF requires analysis of capital expenditure cycle.

Indoco Remedies Limited vs Pharmaceuticals Peers

Peer Comparison - Pharmaceuticals

Compare Indoco Remedies Limited with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
26.9/100
254
₹2344.42
793.8
Average
-9.70%
Poor
1.00%
Poor
1.1
Average
8.25%
Good
0.08%
66.4/100
1861
₹446509.73
36.9
Average
14.74%
Average
19.31%
Good
0.0
Excellent
31.64%
Excellent
11.78%
Good
0.82%
56.3/100
9439
₹250120.25
85.6
Average
16.19%
Good
20.38%
Excellent
0.0
Excellent
5.29%
Good
8.67%
Good
0.41%
51.4/100
4930
₹166860.78
78.8
Average
27.07%
Excellent
14.09%
Average
1.8
Average
11.56%
Good
11.80%
Good
0.76%
74.1/100
1118
₹111556.44
24.9
Average
19.74%
Good
21.77%
Excellent
0.4
Excellent
18.76%
Excellent
12.45%
Good
0.09%
40.2/100
1373
₹110942.04
32.9
Average
11.82%
Average
15.67%
Good
0.0
Excellent
10.03%
Good
8.01%
Good
0.90%
34.1/100
1945
₹105078.63
96.0
Average
18.19%
Good
21.35%
Excellent
0.5
Excellent
-1.89%
Poor
7.19%
Good
0.13%
24.6/100
1668
₹95999.74
26.1
Average
9.94%
Poor
14.54%
Average
0.2
Excellent
-8.07%
Poor
6.32%
Good
0.26%
41/100
1143
₹95440.50
29.5
Average
11.75%
Average
14.80%
Average
0.2
Excellent
16.54%
Excellent
12.09%
Good
0.65%
83.4/100
2078
₹95007.41
17.2
Average
26.90%
Excellent
31.80%
Excellent
0.3
Excellent
34.39%
Excellent
13.02%
Good
0.72%
61.5/100
2238
₹92445.92
45.2
Average
12.49%
Average
13.56%
Average
0.4
Excellent
10.52%
Good
18.10%
Excellent
0.04%

Indoco Remedies Limited PE Ratio History

Historical price-to-earnings ratio for INDOCO — last 5 years

YearEPS (₹)Price (₹)P/E Ratio
FY 202410.51₹332.2031.6x
FY 202315.42₹395.2025.6x
FY 202216.80₹406.6524.2x

P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.

Indoco Remedies Limited Dividend History

Annual cash dividends paid by INDOCO — dividend yield 0.08%

Financial YearDividends Paid (₹ Cr)
FY 202513.90 Cr
FY 202420.71 Cr
FY 202320.72 Cr
FY 202213.79 Cr

Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.

Indoco Remedies Limited Quarterly Performance

Latest quarterly metrics for INDOCO — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

6.76%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

-281.59%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

8.25%

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

N/A

Compounded annual net profit growth over 5 years

Indoco Remedies Limited Technical Indicators

SMA 50, SMA 200, RSI and volume signals for INDOCO — calculated from daily price history

60RSI 14
Neutral — RSI 60

Momentum is balanced — neither overbought nor oversold.

SMA 50
237
▲ Price above SMA 50 — Short-term bullish
SMA 200
223
▲ Price above SMA 200 — Long-term uptrend
30-Day Avg Volume
1016K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Indoco Remedies Limited Financial Statements

Annual income statement, balance sheet and cash flow for Indoco Remedies Limited (INDOCO) — sourced from NSE/BSE filings.

Financial Results & Statements

Latest quarterly, annual and period-wise financial data for Indoco Remedies Limited

Loading latest quarterly results...

About INDOCO (Indoco Remedies Limited)

Indoco Remedies Ltd is a fully integrated, research-oriented pharmaceutical company engaged in the development, manufacturing, and marketing of a wide range of finished pharmaceuti...cal dosages. With a strong emphasis on innovation and quality, Indoco has built a reputation for delivering effective and affordable healthcare solutions across diverse therapeutic segments. Their expansive product portfolio caters to both domestic and international markets, solidifying their position as a trusted partner in the global pharmaceutical landscape. Driven by a commitment to scientific excellence and ethical business practices, Indoco continuously strives to improve patient outcomes and contribute to the advancement of healthcare worldwide, all while maintaining rigorous adherence to international regulatory standards. The company's therapeutic focus is exceptionally broad, encompassing critical areas such as pain management, diabetes care, cardiovascular health, and women's health. Indoco's product offerings include a diverse range of formulations, including tablets, capsules, injectables, and topical preparations, each developed with a meticulous attention to detail and adherence to strict quality control measures. By leveraging cutting-edge technology and a highly skilled workforce, Indoco remains at the forefront of pharmaceutical innovation, constantly seeking to develop novel and improved therapies that address unmet medical needs. The company's strategic partnerships and collaborations further enhance its capabilities and expand its reach, ensuring that its products are accessible to patients across the globe. Indoco's commitment to sustainable growth is evident in its continuous investments in research and development, manufacturing infrastructure, and human capital. The company operates state-of-the-art manufacturing facilities that are compliant with international regulatory standards, ensuring the consistent production of high-quality pharmaceutical products. Furthermore, Indoco places a strong emphasis on environmental sustainability, implementing eco-friendly practices throughout its operations. By combining its dedication to scientific advancement with a responsible and ethical approach to business, Indoco Remedies Ltd is poised to continue its trajectory of growth and contribute meaningfully to the health and well-being of communities worldwide.

Company Details

Symbol:INDOCO
Industry:Pharmaceuticals
Sector:Pharmaceuticals

Key Leadership

Mr. Suresh Govind Kare
Non-Executive Chairman & Whole time Director
Mr. Sundeep Vasant Bambolkar
Joint MD & Executive Director
Ms. Aditi Milind Panandikar
MD & Executive Director

INDOCO Share Price: Frequently Asked Questions

What is the current share price of Indoco Remedies Limited?

Indoco Remedies Limited (INDOCO) trades at ₹254.00 on NSE and BSE. Market cap ₹2.34K (Cr). Educational data only.

What is the P/E ratio of Indoco Remedies Limited?

Indoco Remedies Limited has a P/E of 793.75x vs industry average 34.89x.

What is the Bull Run score for Indoco Remedies Limited?

Indoco Remedies Limited has a Bull Run score of 26.9/100 based on 25+ financial parameters.

Does Indoco Remedies Limited pay dividends?

Indoco Remedies Limited has a dividend yield of 0.08%. Past dividends don't guarantee future payments.

What is the ROE of Indoco Remedies Limited?

Indoco Remedies Limited has ROE of -9.70%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Indoco Remedies Limited?

Indoco Remedies Limited has debt-to-equity of 1.10.

Is Indoco Remedies Limited a good investment?

Bull Run gives Indoco Remedies Limited a score of 26.9/100. This is not investment advice — consult a SEBI-registered advisor.